Scancell : Positive Data for SCIB1, 19th September 2023

DEVELOPING ANTIBODIES AND VACCINES FOR CANCER

Positive Clinical Data for SCIB1 from first stage of Phase 2 SCOPE study

19 September 2023

LSE: SCLP.L

Scancell at a glance

USP: Novel targets in immuno-oncology

World-leader in antibodies

and vaccines

• Clinical stage company with two cancer vaccines in the clinic
• Groundbreaking science leads to validated preclinical results and rapid entry into the clinic
• Strong patent position: 19 patent families
• Impressive early clinical results for
  'end of the road' cancer patients with unmet needs

Specialist investor backing

and strong financial

position

• AIM listed and backed by blue chip specialist biotech investors (Redmile Group (29.4%), Vulpes 14%))
• Well-funded with cash through to H2 2024, with £85m raised to date, £48m in the last 3 years
• Active licensing discussions ongoing further to the licensing deal with Genmab for one of our five mAbs - milestones of up to $624m and single digit royalties

Experienced team focused

on delivery

• Experienced board, leadership and skilled scientific teams with a track record of delivering multiple
  'in-house' and clinically and commercially validated assets
• Lean focused organisation: 61 employees focusing on achieving milestones for lead candidates
• Expanding commercial and clinical development capability in-houseto drive products forward in efficient timelines

September 23

2

Scancell development highlights

Clinically validated vaccine and antibody technology platforms with multiple value drivers

Non-personalised cancer Vaccines

Vaccine platform 1(SCIB1 from Immunobody®):

• Impressive phase 2 early efficacy data obtained on the first 11 evaluable patients treated with a combo vaccine/CPIs in cutaneous melanoma showed an 82% objective response rate (ORR) to treatment
• No toxicity from SCIB1 alone or when added to CPI treatment
• These results are so strong there is a greater than 90% probability they will be confirmed in the larger patient cohort H1 2024.
• Potential to become the new benchmark for unresectable metastatic melanoma treatment (a $1.5bn market)

Vaccine platform 2 (Modi-1 from Moditope®):

• Currently in Phase 2 trial for Head and Neck and Renal Carcinoma (two strong unmet medical needs)
• 11 patients are ongoing treatment
• Results with MODI-1 with checkpoint inhibitors are expected in 2024

►

►

►

Antibodies

A source of non dilutive cash with out licensing opportunities for a range of antibodies

Interest expressed by 3 biotechs for ADC and CART applications.

Validated by Genmab in a $624M license agreement for one of the antibodies to treat one of the most difficult cancer: pancreas

Revenues from preclinical antibody platform partially de-risks the

business model by providing non dilutive cash

September 23

3

SCIB1 for unresected metastatic melanoma

Stimulating potent killer T cells

September 23

4

Oncology Vaccine Overview

• Personalised mRNA vaccines (e.g., Moderna, BioNTech) pose economic and technical challenges
• • Not off the shelf, several weeks to prepare, need a biopsy, adding to cost to make and distribute
  • Uses multiple unvalidated epitopes which limits efficacy
• Scancell's DNA vaccine technologies unlock potential for a universal cancer vaccine
• • A DNA vaccine inducing potent cytotoxic CD8 T cell responses against multiple epitopes with a dual mechanism of action - attacking cancer on multiple fronts
  • Direct and indirect Fc targeting of activated dendritic cells
  • Limited toxicity from SCIB1 alone or when added to CPI treatment
  • Off the shelf, 'easy' to make and distribute, to be used in unresectable melanoma, pricing flexibility
  • Needle free delivery: patient's favourite
• Improved efficacy in combination with CPI therapy… riding the tail of the leaders
• • Synergy (not competition) with immunotherapies and checkpoint inhibitors (CPI market size predicted to be >$50 billion by 2027*)
  • • CPIs open up immune access to the tumour
    • Scancell vaccines boost the immune system to attack the exposed tumours

September 23

*Source: Market Data Forecast report January 2022

5